Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ABUS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ABUS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Arbutus Biopharma Corp

ABUS
Current price
3.24 USD +0.05 USD (+1.57%)
Last closed 3.19 USD
ISIN CA03879J1003
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 620 547 520 USD
Yield for 12 month -0.61 %
1Y
3Y
5Y
10Y
15Y
ABUS
21.11.2021 - 28.11.2021

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania. Address: 701 Veterans Circle, Warminster, PA, United States, 18974

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.38 USD

P/E Ratio

Dividend Yield

Financials ABUS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ABUS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+6 171 000 USD

Last Year

+18 141 000 USD

Current Quarter

+1 764 000 USD

Last Quarter

+1 574 000 USD

Current Year

+4 791 000 USD

Last Year

-55 559 000 USD

Current Quarter

-7 195 000 USD

Last Quarter

+1 241 000 USD
EBITDA -66 183 000 USD
Operating Margin TTM -738.49 %
Price to Earnings
Return On Assets TTM -31.58 %
PEG Ratio
Return On Equity TTM -79.02 %
Wall Street Target Price 5.38 USD
Revenue TTM 6 403 000 USD
Book Value 0.41 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 15.10 %
Dividend Yield
Gross Profit TTM -41 190 000 USD
Earnings per share -0.41 USD
Diluted Eps TTM -0.41 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation ABUS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 79.50
Price Sales TTM 96.92
Enterprise Value EBITDA -5.64
Price Book MRQ 7.84

Technical Indicators ABUS

For 52 Weeks

2.71 USD 4.73 USD
50 Day MA 3.35 USD
Shares Short Prior Month 12 751 934
200 Day MA 3.48 USD
Short Ratio 18.60
Shares Short 12 841 350
Short Percent 9.52 %